Chevalier Isabelle, Beck Carolyn E, Doré-Bergeron Marie-Joëlle, Orkin Julia
Canadian Paediatric Society, Acute Care Committee, Community Paediatrics Committee, Ottawa, Ontario, Canada.
Paediatr Child Health. 2022 Dec 27;27(8):503-511. doi: 10.1093/pch/pxac068. eCollection 2022 Dec.
Clinical symptoms attributed to gastro-esophageal reflux disease (GERD) in healthy term infants are non-specific and overlap with age-appropriate behaviours. This practice point reviews the evidence for medically recommended management of this common condition. Current recommendations to manage GERD include feeding modifications such as thickening feeds or avoiding cow's milk protein. There is limited evidence for pharmacological management, including acid suppressive therapy or prokinetic agents, with the risks of such treatments often outweighing possible benefits due to significant safety and side effect concerns. Acid-suppressive therapy should not be routinely used for infants with GERD and is most likely to be useful in the context of symptoms that suggest erosive esophagitis. Evidence for managing symptoms attributed to GERD in otherwise healthy term infants less than 1 year of age is presented, and the over-prescription of medications in this population is discouraged. Anticipatory guidance regarding the natural resolution of reflux symptoms is recommended.
健康足月儿出现的归因于胃食管反流病(GERD)的临床症状不具有特异性,且与适合其年龄的行为表现相重叠。本实践要点回顾了针对这种常见病症进行医学推荐管理的证据。目前管理GERD的建议包括喂养方式的调整,如增加奶液浓稠度或避免摄入牛奶蛋白。药物治疗方面的证据有限,包括抑酸治疗或促动力药物,由于存在重大的安全性和副作用问题,此类治疗的风险往往超过可能带来的益处。抑酸治疗不应常规用于患有GERD的婴儿,最有可能在提示糜烂性食管炎的症状背景下有用。本文呈现了针对1岁以下其他方面健康的足月儿中归因于GERD的症状进行管理的证据,并不鼓励对该人群过度开药。建议提供关于反流症状自然缓解的预期指导。